Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced its financial results for the year ended December 31, 2025, revealing a consolidated net loss of $122.9 million, or $0.44 per share, compared to a net loss of $97.9 million, or $0.49 per share, for the previous year. The company reported revenues of $39.6 million for 2025, a decrease from $57.8 million in 2024, primarily due to a significant drop in revenue from its collaboration agreement with Genentech. However, the company highlighted positive developments in its clinical pipeline, including the ongoing rolling submission of a Biologics License Application (BLA) for its gene therapy product candidate, ST-920, aimed at treating Fabry disease. The FDA has indicated that the positive topline results from the registrational STAAR study may serve as a primary basis for approval under the Accelerated Approval pathway. Additionally, Sangamo has transitioned to a clinical-stage neurology company, activating six clinical sites for its Phase 1/2 STAND study in chronic neuropathic pain. The company has also secured over $130 million in funding since the beginning of 2025 through non-dilutive license fees and milestone payments, as well as equity financing. Despite the financial losses, Sangamo's strategic advancements and ongoing clinical trials position it for potential future growth.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.